Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IRVING K LOH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1750449856
CMS profile
33860
Location
THOUSAND OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$156,570.33

231 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IRVING K LOH

NPI 1750449856 · CMS profile ID 33860

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

THOUSAND OAKS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750449856?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IRVING K LOH, NPI 1750449856, CMS profile ID 33860. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750449856?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). IRVING K LOH, NPI 1750449856, CMS profile ID 33860. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750449856?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
IRVING K LOH, NPI 1750449856, CMS profile ID 33860, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750449856?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

231 matching records · $156,570.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 231 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 231.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $38.2806/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699167529 CMS
Amarin Pharma Inc. $3,750.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699170987 CMS
Amgen Inc. $2,800.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411343 CMS
Amgen Inc. $1,868.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411353 CMS
Amgen Inc. $22.4806/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411357 CMS
Amgen Inc. $13.4206/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411361 CMS
Amgen Inc. $2,800.0006/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411425 CMS
Amgen Inc. $1,471.8506/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411372 CMS
SANOFI-AVENTIS U.S. LLC $19.9606/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694075811 CMS
AstraZeneca Pharmaceuticals LP $17.0506/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685214633 CMS
Amgen Inc. $579.3006/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411377 CMS
Amgen Inc. $12.8006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411333 CMS
Amgen Inc. $63.4906/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411409 CMS
Medtronic Vascular, Inc. $17.1006/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676948251 CMS
Novartis Pharmaceuticals Corporation $37.1106/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659612383 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $18.6606/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625178789 CMS
Amgen Inc. $2,800.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411338 CMS
Amgen Inc. $467.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411347 CMS
Amgen Inc. $629.2005/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411367 CMS
Amgen Inc. $2,800.0005/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411387 CMS
Amarin Pharma Inc. $15.9805/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699147583 CMS
Amgen Inc. $21.4605/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411391 CMS
Amgen Inc. $121.8805/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411381 CMS
Amgen Inc. $791.6805/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411449 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $19.2605/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625178787 CMS
Amarin Pharma Inc. $3,750.0005/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699137209 CMS
Amarin Pharma Inc. $20.9004/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699135449 CMS
Amarin Pharma Inc. $98.4204/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699133257 CMS
Amarin Pharma Inc. $313.7204/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699136599 CMS
Amarin Pharma Inc. $159.4804/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699138285 CMS
Amarin Pharma Inc. $30.0004/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699138295 CMS
SANOFI-AVENTIS U.S. LLC $24.9204/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693999925 CMS
Amarin Pharma Inc. $3,750.0004/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699130685 CMS
Amgen Inc. $5.0004/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411203 CMS
Amgen Inc. $29.5004/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411211 CMS
Amgen Inc. $5.0004/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411239 CMS
Amgen Inc. $31.7804/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411265 CMS
SANOFI-AVENTIS U.S. LLC $31.8204/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694041787 CMS
AstraZeneca Pharmaceuticals LP $16.3404/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685125887 CMS
SANOFI-AVENTIS U.S. LLC $24.9004/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693994777 CMS
Amgen Inc. $2,800.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411207 CMS
Amgen Inc. $2,800.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411245 CMS
Amgen Inc. $2,800.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411249 CMS
Amgen Inc. $2,800.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411255 CMS
Amgen Inc. $2,800.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411299 CMS
Amgen Inc. $1,868.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411307 CMS
Amarin Pharma Inc. $7.0004/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699120569 CMS
Amarin Pharma Inc. $124.8504/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699122249 CMS
Amarin Pharma Inc. $5.3404/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699122257 CMS
Amgen Inc. $5.0004/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662411295 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $156,570.33 231
PY2020 $30,282.25 42
PY2021 $2,763.34 23
PY2022 $290.93 11
PY2023 $1,040.38 9
PY2024 $3,972.77 36
PY2025 $1,060.83 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,355.15 15
PY2025 Principal investigator $529,552.45 33
PY2024 Recipient $15,129.25 2
PY2024 Principal investigator $357,141.82 8
PY2021 Principal investigator $867.94 2
PY2020 Recipient $11,500.00 4
PY2020 Principal investigator $6,425.00 2
PY2019 Recipient $11,500.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 12/30/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770357
Principal investigator 1 Boehringer Ingelheim International GmbH $21.75 12/30/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770359
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 12/30/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770361
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770363
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770333
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770335
Principal investigator 1 Boehringer Ingelheim International GmbH $1,254.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770337
Principal investigator 1 Boehringer Ingelheim International GmbH $2,766.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770339
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770341
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770343
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770345
Principal investigator 1 Boehringer Ingelheim International GmbH $1,750.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770347
Principal investigator 1 Boehringer Ingelheim International GmbH $2,145.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770349
Principal investigator 1 Boehringer Ingelheim International GmbH $815.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770351
Principal investigator 1 Boehringer Ingelheim International GmbH $12,000.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770353
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 12/03/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770355
Principal investigator 1 Eli Lilly and Company $199.90 11/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187878319
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/01/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220998419
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,650.00 08/20/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185553439
Principal investigator 1 Novartis Pharmaceuticals Corporation $28.68 08/14/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190312757
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770327
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 07/28/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770329
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Care Access Research-Thousand Oaks
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220770331
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,400.00 07/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185553433
Principal investigator 1 Eli Lilly and Company $172,023.00 06/16/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187876503
Principal investigator 1 Eli Lilly and Company $7.70 06/10/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187875623
Recipient Boehringer Ingelheim International GmbH $355.54 05/08/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779992
Recipient Boehringer Ingelheim International GmbH $303.60 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779966
Recipient Boehringer Ingelheim International GmbH $20.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779970
Recipient Boehringer Ingelheim International GmbH $57.19 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779972
Recipient Boehringer Ingelheim International GmbH $40.45 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779974
Recipient Boehringer Ingelheim International GmbH $38.36 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779976
Recipient Boehringer Ingelheim International GmbH $124.99 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779978
Recipient Boehringer Ingelheim International GmbH $263.22 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779980
Recipient Boehringer Ingelheim International GmbH $60.06 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779982
Recipient Boehringer Ingelheim International GmbH $62.39 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779984
Recipient Boehringer Ingelheim International GmbH $20.00 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779986
Recipient Boehringer Ingelheim International GmbH $123.97 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779988
Recipient Boehringer Ingelheim International GmbH $7.01 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779990
Recipient Boehringer Ingelheim International GmbH $13.24 05/07/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779994
Recipient Boehringer Ingelheim International GmbH $1,865.13 04/29/2025 Covered Recipient Physician EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220779968
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $4,646.34 04/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187878575
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,652.28 03/14/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185553437
Principal investigator 1 Eli Lilly and Company $4,431.90 01/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882744
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,939.00 01/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190311141
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,460.33 01/10/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185553435
Principal investigator 1 Eli Lilly and Company $182,814.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876493
Principal investigator 1 Eli Lilly and Company $58,821.20 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187877981